MV130 (Bactek) and mesenchymal stem cells


Frontiers in Immunology publishes a study on the effect of MV130 (Bactek) on mesenchymal stem cells. These cells are acquiring a leading role not only for their differentiation capacity but also for their emerging immunomodulatory activity. Mesenchymal stem cells can take up the bacteria contained in MV130 and modify their functionality towards pro and anti-inflammatory responses in a controlled sequential way.

logo PNID2

National Innovation Award to INMUNOTEK

, , ,

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of “Small and Medium-Sized Enterprise”.

Jornada Eliseo Subiza_olivo

The olive tree protagonist in the “Eliseo Subiza” Botanical Day


The XXII Botanical Identification Seminar Day “Eliseo Subiza” was dedicated to the olive tree and took place in Toledo. This initiative of the Hospital Virgen del Valle (Toledo) has the collaboration of INMUNOTEK and is aimed to perform a botanical training of young allergists in main local allergenic plants. Through field trips with botanical experts and aerobiological lectures, each year is dedicated to special plant. The olive tree is a tree of great allergological interest as a cause of pollinosis in Spain since its pollen is very allergenic and affects a large number of patients.

INMUNOTEK revalidates its Innovative SME stamp


INMUNOTEK revalidates its Innovative SME stamp issued by the Spanish Government at the Directorate General for Innovation and Competitiveness of the Ministry of Economy. This stamp was granted to INMUNOTEK in 2015.


Clinical trial with UROMUNE in UK


A recent study with UROMUNE (MV140) published in the British Journal of Urology International demonstrates its efficacy in the treatment of recurrent urinary tract infections. This condition has a considerable morbidity worldwide and requires the continued use of antibiotics.

vacunas alergia

Novel glycoconjugates with allergoids


It has been published in the Glycoconjugate Journal an original article related to the mannan-allergoid glycoconjugates developed by INMUNOTEK for novel allergy vaccines.